629658-06-6

Usage

Uses

Used in Organic Synthesis:
3-Chloro-4-hydroxyphenylboronic acid, pinacol ester is used as a building block for the construction of complex organic molecules, facilitating the formation of carbon-carbon and carbon-heteroatom bonds. Its reactivity and versatility make it a key component in various synthetic pathways.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 3-Chloro-4-hydroxyphenylboronic acid, pinacol ester is used as a key intermediate in the development of potential drug candidates and bioactive compounds. Its ability to participate in cross-coupling reactions and other related transformations allows for the creation of novel and diverse molecular structures with potential therapeutic applications.
Used in Cross-Coupling Reactions:
3-Chloro-4-hydroxyphenylboronic acid, pinacol ester is utilized as a reactant in cross-coupling reactions, which are essential for the formation of carbon-carbon bonds in organic synthesis. These reactions enable the creation of a wide range of molecular structures with potential applications in various fields, including pharmaceuticals, materials science, and agrochemicals.
Overall, 3-Chloro-4-hydroxyphenylboronic acid, pinacol ester has a broad range of applications in the fields of organic chemistry and pharmaceutical science, making it an indispensable tool for researchers and chemists working on the development of new compounds and materials.

InChI:InChI=1/C12H16BClO3/c1-11(2)12(3,4)17-13(16-11)8-5-6-10(15)9(14)7-8/h5-7,15H,1-4H3

Upstream product

• 3964-56-5 4-bromo-2-chlorophenol 
• 73183-34-3 bis(pinacol)diborane 
• 95-57-8 2-monochlorophenol 

Downstream Products

• 1430471-78-5 tert-butyl 4-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperidine-1-carboxylate 
• 1430471-79-6 4-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)-1-methylpiperidine 
• 1616917-74-8 C₂₁H₂₄BClO₃ 
• 1616917-81-7 (E)-2-chloro-4-cinnamylphenol 
• 1616917-82-8 (E,E)-2-chloro-4-cinnamyl-1-(cinnamyloxy)benzene 
• 364354-03-0 2-(3-chloro-4-phenoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 

Relevant academic research and scientific papers

Fragment-Based Discovery of 6-Arylindazole JAK Inhibitors

Janus kinase (JAK) inhibitors are emerging as novel and efficacious drugs for treating psoriasis and other inflammatory skin disorders, but their full potential is hampered by systemic side effects. To overcome this limitation, we set out to discover soft drug JAK inhibitors for topical use. A fragment screen yielded an indazole hit that was elaborated into a potent JAK inhibitor using structure-based design. Growing the fragment by installing a phenol moiety in the 6-position afforded a greatly improved potency. Fine-tuning the substituents on the phenol and sulfonamide moieties afforded a set of compounds with lead-like properties, but they were found to be phototoxic and unstable in the presence of light.

Para-Selective C-H Borylation of Common Arene Building Blocks Enabled by Ion-Pairing with a Bulky Countercation

The selective functionalization of C-H bonds at the arene para position is highly challenging using transition metal catalysis. Iridium-catalyzed borylation has emerged as a leading technique for arene functionalization, but there are only a handful of strategies for para-selective borylation, which operate on specific substrate classes and use bespoke ligands or catalysts. We describe a remarkably general protocol which results in para-selectivity on some of the most common arene building blocks (anilines, benzylamines, phenols, benzyl alcohols) and uses standard borylation ligands. Our strategy hinges upon the facile conversion of the substrates into sulfate or sulfamate salts, wherein the anionic arene component is paired with a tetrabutylammonium cation. We hypothesize that the bulk of this cation disfavors meta-C-H borylation, thereby promoting the challenging para-selective reaction.

Para-Selective, Iridium-Catalyzed C-H Borylations of Sulfated Phenols, Benzyl Alcohols, and Anilines Directed by Ion-Pair Electrostatic Interactions

Para C-H borylations (CHB) of tetraalkylammonium sulfates and sulfamates have been achieved using bipyridine-ligated Ir boryl catalysts. Selectivities can be modulated by both the length of the alkyl groups in the tetraalkylammonium cations and the substituents on the bipyridine ligands. Ion pairing, where the alkyl groups of the cation shield the meta C-H bonds in the counteranions, is proposed to account for para selectivity. The 4,4′-dimethoxy-2,2′-bipyridine ligand gave superior selectivities.

2- PYRIDONE COMPOUND

PROBLEM TO BE SOLVED: To provide a compound that has excellent glucokinase (GK) activating action and is useful as a pharmaceutical. SOLUTION: The present invention provides a 2-pyridone compound represented by formula [1], and a tautomer or stereoisomer of the compound, or their pharmacologically acceptable salts, or their solvates (where R1 is RA-ZA-; RA is any of a carboxy group, a sulfo group or formula [5]). COPYRIGHT: (C)2016,JPOandINPIT

BIARYL DERIVATIVES AS GPR120 AGONISTS

The present invention relates to biaryl derivatives of Formula 1, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The biaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in the liver or in muscle due to anti-inflammatory action in macrophages, lipocytes, etc., and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, obesity, non-alcoholic fatty liver, steatohepatitis, osteoporosis or inflammation.

SUBSTITUTED PYRAZOLOPYRIMIDINES AS KINASES INHIBITORS

The present invention is directed to novel pyrazolopyrimidines, their derivatives, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions of the present invention have protein kinases inhibitory activities against BTK and/or EGFR T790M and are useful for the treatment of protein kinases mediated diseases and conditions.

Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors

A series of hydroxamic acid-based histone deacetylase (HDAC) inhibitors were designed on the basis of a model of the HDAC2 binding site and synthesized. They are characterized by a cinnamic spacer, capped with a substituted phenyl group. Modifications of the spacer are also reported. In an in vitro assay with the isoenzyme HDAC2, a good correlation of the activity with the docking energy was found. In human ovarian carcinoma IGROV-1 cells, selected compounds produced significant acetylation of p53 and α-tubulin. Most compounds showed an antiproliferative activity comparable to that of SAHA. At equitoxic concentrations, the tested compounds were more effective than SAHA in inducing apoptotic cell death. Compounds selected for in vivo evaluation exhibited a significant antitumor activity on three tumor models at well tolerated doses, thus suggesting a good therapeutic index.

PROTEIN KINASE INHIBITORS

A compound of general formula (I) or pharmaceutically acceptable salts, hydrates, solvates, crystal forms of diastereomers thereof is described. A method of treating protein kinase-associated disease states using the compound of Formula (I) is also described.